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ABSTRACT

Background: Prior research has widely recognized neurocognitive impairment (NCI), HIV risk
reduction self-efficacy, and gender as important predictors of HIV risk reduction intervention
outcomes. No studies to date, however, have explored how these variables interact with each
other, and the combined effects when taken together on HIV risk reduction behaviors. This
paper incorporated a moderated mediation model to examine whether the indirect effect of NCI
on HIV risk reduction intervention outcomes via self-efficacy related to HIV risk reduction
varies by gender among people who use drugs (PWUDs) in treatment.
Method: Two hundred and thirty six HIV-negative opioid-dependent individuals newly
enrolled in a methadone maintenance treatment (MMT) and reporting drug- and/or sex-related
HIV risk behaviors completed an audio-computer-assisted self-interview (ACASI) that
measured NCI, HIV risk reduction self-efficacy (i.e., drug and sex-related) and HIV risk
reduction outcomes (i.e., drug- and sex-related) over time. We used a linear model path analytic
framework to test the moderated mediation models for drug- and sex-related HIV risk reduction
variables (i.e., clean needle use and consistent condom use).
Results: Results showed that a higher degree of NCI significantly predicted lower levels of safe
injection self-efficacy (β=-0.0160, p=0.0160) and clean needle use (β=-0.006, p=0.03).
Moreover, the indirect effect of NCI on clean needle use was mediated via safe injection selfefficacy (β=-0.0016, p=0.02, proportion mediated = 25%). Similarly, a higher degree of NCI
significantly predicted lower levels of safe sex self-efficacy (β=-0.0231, p=0.0238), but not
condom use (β=-0.0008, p=0.81). However, the indirect effect of NCI on consistent condom
xiii

use was mediated via safe sex self-efficacy (β=-0.003, p=0.02, proportion mediated = 59%).
Further, these effects were moderated by gender, with only females showing significant
mediation effects of self-efficacy for both clean needle use and condom use.
Conclusion: The findings make an important contribution to our understanding of the utility of
a moderated mediation model. Our model showed, such that there was a differential indirect
effect of NCI on HIV risk reduction intervention outcomes via self-efficacy between males and
females.

xiv

CHAPTER 1 : Introduction

Despite a wide array of preventive efforts, approximately 50,000 new HIV infections
are diagnosed per year in the United States. (Centers for Disease Control and Prevention, 2014).
From the beginning of HIV era, drug abuse has been a well-established risk factor of HIV
infection (Centers for Disease Control and Prevention, 2013). People who use drugs (PWUDs)
represent a critical conduit for the transmission of new HIV infection through drug-related (e.g.,
needle sharing) and sex-related (e.g., inconsistent condom use) HIV risk behaviors (Arasteh,
Des Jarlais, & Perlis, 2008; Baron & Kenny, 1986; Li et al., 2013; Marshall et al., 2014; MateuGelabert et al., 2016; Noar, 2008; Pitpitan et al., 2015; Strathdee et al., 2010; Volkow &
Montaner, 2011). Although the number of new HIV infections attributed to PWUDs has
decreased in recent years (Centers for Disease Control and Prevention, 2014), they still remain
as priority populations for prevention of HIV because of their significant association with HIV
risk behaviors.
Prior research suggests both drug abuse and HIV infection can lead to neurocognitive
impairment (NCI) (Anand, Springer, Copenhaver, & Altice, 2010; Antinori et al., 2007;
Clifford & Ances, 2013; Heaton et al., 2011; Indlekofer et al., 2009; Lundqvist, 2005; Schouten,
Cinque, Gisslen, Reiss, & Portegies, 2011; Vik, Cellucci, Jarchow, & Hedt, 2004; Woicik et
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al., 2009) that exhibited a noteworthy association with drug-related and sex-related HIV risk
behaviors (Anand et al., 2010; Mitchell, Severtson, & Latimer, 2007; Shrestha & Copenhaver,
2016; Stacy, Newcomb, & Ames, 2000). In addition, NCI reduces medication adherence
(Anand et al., 2010; Ezeabogu, Copenhaver, & Potrepka, 2012; Lovejoy & Suhr, 2009).
Overall, increased risk behaviors and suboptimal adherence demonstrated by individuals who
have NCI diminishes the effectiveness of interventions aimed to reduce new HIV infection
(Anand et al., 2010; Shrestha, Huedo-Medina, & Copenhaver, 2015). Furthermore, HIV
prevention interventions often involve learning and retaining new information, inhibiting
impulsive responses, and engaging in future-oriented behaviors that place high demand on
various cognitive domains, like memory, learning, and attention. Among drug users, however,
neurocognitive domains that are commonly compromised include executive functioning,
information processing, motor functioning, attention, learning, and memory (Anand et al.,
2010; Lovejoy & Suhr, 2009). Impairment of these domains also can negatively influence the
potency of the intervention. Given the impact of NCI on intervention effectiveness, it is crucial
to understand the underlying mechanisms through which NCI may influence treatment
outcomes.
One construct thought to be important in promoting positive intervention outcomes is
self-efficacy - developing a sense of personal power to exercise control over situations,
including risk reduction skills (Bandura, 1990). Prior research has shown self-efficacy to be a
strong predictor of improved treatment outcomes (Bandura, 1990; Burleson & Kaminer, 2005),
and lower self-efficacy is associated with higher levels of HIV risk behaviors (Bedoya et al.,
2012; Nehl, Klein, Sterk, & Elifson, 2015; Puffer et al., 2011; Thomas et al., 2009; Winningham
et al., 2004). Self-efficacy has been shown to serve as a mediator between norms for condom
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use and unsafe sex (Miner, Peterson, Welles, Jacoby, & Rosser, 2009), and intervention
significantly influenced needle sharing via safe injection self-efficacy (Pitpitan et al., 2015).
Thus, it is important to examine the extent to which self-efficacy stemming from behavioral
interventions may be negatively influenced by a participant’s NCI, as is expected based on
recent work in this area (Worley, Tata, Granholm, & Brown, 2014). To date, very few studies
have examined how NCI may influence self-efficacy and, ultimately, treatment outcomes.
Another construct of relevance to intervention outcomes pertains to gender. Gender
difference plays a significant role in both self-efficacy and intervention outcomes (Buchanan et
al., 2006; M. M. Copenhaver, Lee, & Baldwin, 2013; Corsi et al., 2014; Lee, Salman, &
Cooksey-James, 2016; Puffer et al., 2011; Stevens, Murphy, & McKnight, 2003; Zandmomen
et al., 2014). Moreover, some studies report greater NCI in women than men (Gandhi et al.,
2010; Royal et al., 2016; Shrestha et al., 2015; Troncoso & Conterno, 2015). Thus, examining
the interacting effects of gender, NCI, and self-efficacy on HIV risk behavior is of particular
relevance to future intervention efforts.
The purpose of the present study is to explore the indirect effect of NCI on HIV
preventive behaviors (i.e., clean needle use and condom use) via self-efficacy. Given the
established relationship between gender with NCI, self-efficacy, and HIV risk behavior
(Buchanan et al., 2006; M. M. Copenhaver et al., 2013; Corsi et al., 2014; Gandhi et al., 2010;
Lee et al., 2016; Puffer et al., 2011; Royal et al., 2016; Shrestha et al., 2015; Stevens et al.,
2003; Troncoso & Conterno, 2015; Zandmomen et al., 2014), we also aim to explore whether
this indirect effect is moderated by gender.
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CHAPTER 2 : Literature Review

2.1 HIV Prevalence
Molecular epidemiologic studies attempted to give an insight into the origin and
geographic diffusion patterns of HIV infection (Inrig, 2015). The virus is assumed to have
entered human populations through cross-species transmission of related chimpanzee
retroviruses found in western equatorial Africa in the early twentieth century (Sharp & Hahn,
2011). From the beginning of HIV epidemic, Sub-Saharan Africa is the most severely affected
region, accounting for 71% of all new HIV infections in 2008 (Unaids, 2009).
As a whole, the HIV epidemic has changed over the past 20 years, from the highest
estimated new infections of 3.7 million in 1997, to declining new infections and AIDS-related
mortality throughout the 2000s (Figure 1) (Unaids, 2013). There were 2.1 million new HIV
infections in 2013 - a decline of 38% from 2001, when there were around 3.4 million new
infections (UNAIDS, 2014). Among 35 million people living with HIV infection globally in
2013, 46% were women or girls elder than 15 years. At the end of 2013, 12.9 million people
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receiving antiretroviral therapy globally. As more people are receiving life-saving antiretroviral
therapy, there was a decline in the number of AIDS deaths with 1.5 million in 2013 from 2.3
million in 2005, when the highest number of deaths were recorded. As a result, there was an
increase in people living with HIV from previous years (Figure 2). Advancement has been
dramatic in decreasing new HIV infections among children. In 2013, about 240 000 children
were newly infected with HIV, which is 58% lower than in 2002, when the highest number of
children, around 580 000, became newly infected with HIV (UNAIDS, 2014). Though HIV
incidence is declining, certain group of populations are at high risk of being infected. World
Health Organization (WHO) defined five key populations who are at increased risk of HIV.
Usually, the social and legal issues related to their behaviors increase their susceptibility to
HIV, irrespective of the epidemic type or local context. The five key populations include men
who have sex with men (MSM), people who inject drugs (PWIDs), people in prisons and other
closed settings, sex workers, and transgender people (WHO, 2014). Recent studies indicated
elevated level of infections in these populations nearly in all regions (Unaids, 2009).
In the United States, more than 1.2 million people are living with HIV and 12.8% of
them are unware of their status. The estimated new HIV infection has remained stable in recent
years – at about 50,000 per year. But the rate of new infection is particularly high among certain
groups. Gay, bisexual, and other men who have sex with men (MSM) bears the greatest burden
of HIV infection and African Americans are disproportionately affected. MSM represented
78% of new HIV infections among males and 63% of all new infections in 2010. On the other
hand, among females, major route of transmission of HIV were heterosexual contact (84%) or
injection drug use (16%) in 2010. Overall, injection drug users accounted for 8% of new HIV
infections in 2010 and 15% of those living with HIV in 2011 (CDC, 2015). HIV incidence is

~5~

concentrated primarily in large U.S. metropolitan areas (81% in 2011), with New York, Los
Angeles, and Miami topping the list. Regionally, the incidence is highest in the South,
accounted for about half (48%) of new HIV diagnoses in 2011. But taking population into
account, the rate is highest in the Northeast followed by South, West and Mid-west (Centers
for Disease Control and Prevention, 2014).

Figure 1: Number of people newly infected with HIV [Global, 1990-2011]

Figure 2: Number of people living with HIV [Global, 1990-2011]
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2.2 HIV and Substance Abuse
Substance abuse, is defined as the use of illicit and self-damaging recreational or
prescription drugs or chemicals that lead to an inability to control the use of that substance.
From the beginning of HIV epidemic, substance use, abuse, and dependence have been a wellestablished risk factor of HIV infection. Injection drug use (IDU) is a direct route of
transmission of HIV (Centers for Disease Control and Prevention, 2013). IDU is responsible
for significant proportion of new HIV infections in many parts of the world, including countries
in Eastern Europe, South America, and East and Southeast Asia (UNAIDS, 2012). In 2010, 8%
of new HIV infections in the United States happened via IDU (Figure 3) and men accounted
for 62% of all IDU-associated HIV infections. Half (50%) of the estimated new HIV infection
among injection drug users attributed to African Americans, 26% to white, and 21% to
Hispanics/Latinos.
HIV can be transmitted in this high risk population by sharing needles, syringes, or other
injection equipment (e.g., cookers, rinse water, cotton) that were used by a person living with
HIV. Injection drug use also can alter judgement and reduce inhibitions to take part in risky
behaviors, like not using condoms or taking preventive medicine, such as pre-exposure
prophylaxis (PrEP). In the cities with high HIV prevalence, about one-third of PWID reported
sharing syringes, more than half reported sharing other injection equipment, and 72% of female
injection drug users reported having sex without a condom in the past 12 months. PWID may
also engage in risky sexual behaviors in exchange of drugs (CDC, 2015). Other form of
substance abuse, like drinking, smoking, ingesting, or inhaling drugs such as alcohol, crack
cocaine, methamphetamine (“meth”), and amyl nitrite (“poppers”) may not directly
transmitting HIV, but associated with an increased risk of HIV transmission by reducing users’
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self-consciousness to engage in risky sexual behavior (Centers for Disease Control and
Prevention, 2013). Studies conducted on IDUs also reported significant association between
drug abuse and HIV transmission via injection equipment sharing and unprotected sex. A study
conducted by Arasteh et al., evaluated data from 6341 IDUs entering methadone maintenance
treatment in New York City between 1990 and 2004. They analyzed the relationship of risky
sexual behavior with alcohol intoxication during sex and at-risk drinking (more than 14 drinks
per week for males or 7 drinks per week for females) in the past 6 months. They reported more
unprotected sex with casual sex partners in both conditions, alcohol intoxication during sex and
at-risk drinking in the past 6 months. In case of primary partners, IDUs also reported
unprotected sex when both partners were intoxicated (Arasteh et al., 2008). Another crosssectional study conducted by Mateu-Gelabert et al., assessed injection risk behaviors among
heroin injectors in the Colombian cities of Medellín and Pereira. Researchers conducted a
structured interview of 60 minutes with local PWID by using WHO-II survey, which has been
widely used to study this population and the survey included questions on demographics, drug
use and injection equipment sharing behaviors in the previous 6 months, last injection event,
and HIV knowledge (WHO, 2000). They have found injection equipment sharing was a
common phenomenon among PWID. Forty-eight percent reported syringe sharing and 49%
also reported sharing of cookers, filters, or rinse water. Among those who injected with
previously used syringe, 31% of them reported never cleaning used syringes and those who
cleaned used syringes, only 25% of them used alcohol or cleaning agent. The results of this
study indicated a high prevalence of risky drug injecting behavior among injection drug users,
such as sharing of injection equipment and not cleaning used syringes before injecting (MateuGelabert et al., 2016). In addition to increasing the risk of HIV transmission via drug- and sex-
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related HIV risk behaviors, substance abuse can make individuals more vulnerable to HIV
infection. In those who already infected, substance abuse can accelerate disease progression to
more advanced clinical stages of HIV infection, marked by a high occurrence of opportunistic
infections, non-AIDS-defining illnesses and HIV-related deaths by negatively impacting
adherence to treatment (Centers for Disease Control and Prevention, 2013). A systematic
review and meta-analysis examined mortality rates and causes of death in PWID, and identified
drug overdose and AIDS-related illness to be associated with higher risk of death in this
population (Mathers et al., 2013).
Overall, substance abuse is associated with non-adherence, immunosuppression,
increased risk behaviors, and increased burdens on health care systems. Approximately 50% of
people living with HIV/AIDS reported current or past histories of substance abuse (Figure 4)
(NSDUH, 2010). HIV prevalence among injection drug users is highest in Russia (37%),
followed by USA (16%) and China (12%) (Mathers et al., 2008). Even though the number of
new HIV infections attributed to IDU has reduced in recent years (Centers for Disease Control
and Prevention, 2014), this population remains priority for HIV prevention because of their
significant association with HIV risk behaviors.
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Figure 3: Estimated new HIV infection by transmission category [CDC, 2012]

Figure 4: Lifetime drug use in people living with HIV in USA [NSDUH, 2010]

2.3 Substance Abuse, NCI, and HIV
Cognitive impairment is defined as trouble remembering, learning new things,
concentrating, or making decisions that affect a persons’ everyday life. Cognitive impairment
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ranges from mild to severe. With mild impairment, cognitive functions are impaired, but still
people are able to do their everyday activities. Severe level of impairment can lead to losing the
ability to comprehend the sense or significance of something and the ability to talk or write,
eventually resulting in the incapacity to live independently (CDC, 2010). Currently, in United
States, more than 16 million people are living with cognitive impairment which places
significantly greater demands on health care systems (CDC, 2010). Cognitive impairment is
commonly manifested by memory loss, frequently asking the same question or repeating the
same story over and over, not recognizing familiar people and places, having trouble exercising
judgment, such as knowing what to do in an emergency, changes in mood or behavior, vision
problems, and difficulty planning and carrying out tasks (CDC, 2010).
Drug abuse impacts neurocognitive functioning both directly and indirectly. Drugs
directly impact neurochemical activity of the brain, alter the level of neurotransmitters, and
indirectly impact brain functioning via reducing the cerebral blood flow affecting other organ
systems, especially liver and cerebral vasculature. These direct and indirect effects of drugs on
the brain can cause different degrees of neurocognitive impairment among drug abusers (Vik
et al., 2004). Neurocognitive domains that are commonly compromised by drug abuse include
executive functioning, information processing, motor functioning, attention, learning, and
memory (Anand et al., 2010). Previous studies exhibited significant performance deficits of
attention, executive function, and verbal/working memory in chronic cocaine users (Shrestha
et al., 2015; Vonmoos et al., 2013; Woicik et al., 2009). A study aimed to assess the relationship
between drug abuse and cognitive functioning showed significant association of ecstasy and
cannabis use with poorer episodic memory function and lapses of attention in a dose-related
manner (Indlekofer et al., 2009). Another review article also reported loss of attention and

~ 11 ~

memory in cannabis users and decreased mental flexibility, increased perseveration, and
reduced learning, to shift and/or sustain attention to be associated with heavy cannabis use.
Amphetamine/methamphetamine use also demonstrated deficits in learning, delayed recall,
processing speed, and working memory. MDMA (3,4-methylenedioxymethamphetamine,
ecstasy) users showed difficulties in coding information into long-term memory, impaired
verbal learning, easy distraction, and loss of attention/focus on complex tasks. The degree and
duration of executive impairment increased with the severity of use. Chronic cocaine use caused
impairment of attention, learning, memory, reaction time and cognitive flexibility. Heroin
addiction might negatively impact impulse control, and selective processing (Lundqvist, 2005).
Drug abuse with HIV infection, especially opioids and cocaine, may deteriorate
cognitive functioning by reducing immune system integrity and stimulating viral replication.
Cocaine also increases the permeability of the blood–brain barrier to HIV and promotes cellular
apoptosis, leading to more neurological impairment (Anand et al., 2010). HIV-associated
neurocognitive disorders (HAND) include varying degree of neurocognitive dysfunction,
ranging from severe HIV-associated dementia (HAD) to mild neurocognitive disorder (MND)
and asymptomatic neurocognitive impairment (ANI). The pattern of HAND has rapidly
evolved with the widespread use of antiviral treatment. Before combination antiretroviral
therapy (CART), HAD was more common which is defined by increased loss of attention and
concentration, marked motor slowing, and multiple behavioral components mostly leading to
death in less than a year. During the era of CART, MND and ANI are more common
manifestations of HAND. Cognitive impairment related to HAND in CART era is more similar
to other common degenerative disorders (i.e. Alzheimer's disease) than HAD. HAND
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manifestation from CART era comprised more memory (learning) and executive function
impairment (Clifford & Ances, 2013; Heaton et al., 2011).
Approximately half of all treated HIV patients have neurocognitive disorders. Prior
studies assessing the neurophysiological status of HIV infected individuals among different risk
groups in both European cohort (Chiesi et al., 1996) and American cohort (Nath, Maragos,
Avison, Schmitt, & Berger, 2001; Tyor & Middaugh, 1999), reported higher prevalence of
cognitive disorder in HIV infected drug users than in other groups. Though, the introduction of
CART in 1996 has reduced HIV related severe neurocognitive disorders, such as dementia
(Dore, McDonald, Li, Kaldor, & Brew, 2003; Robertson et al., 2007; N. C. Sacktor et al., 1999,
2000), subtle forms of cognitive impairment continues to be a challenge in CART era (Heaton
et al., 2011; Robertson et al., 2007; N. Sacktor et al., 2002).

2.4 NCI and HIV Risk Behavior
The pattern of cognitive impairment caused by substance abuse and HIV may contribute
to increased HIV risk behavior. Impairment in cognitive function may hinder their rational
decision-making and ability to practice safe drug- and sex-related choices (Anand et al., 2010).
A longitudinal study conducted by Stacy et al. demonstrated that implicit cognition - referring
to the learning, memory, and performance processes which take place without the participants’
conscious awareness - was an independent predictor of unprotected sex in a high-risk sample.
Even, after controlling other potential strong predictors (e.g., drug use, sensation seeking),
implicit cognition remained a significant predictor of unprotected sex (Stacy et al., 2000) Some
recent studies, aimed to determine the effects of impaired cognitive functioning on increased
HIV risk behaviors among HIV negative drug offenders showed that higher working memory
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and affective decision making capacity positively influenced condom use (Ames, Grenard, &
Stacy, 2013; Grenard, Ames, & Stacy, 2013). In one study conducted by Grenard et al., working
memory capacity served as a moderator in the relationship between spontaneous safe sexrelated associations and condom use. Accessibility of spontaneous safe sex-related associations
significantly predicted higher condom use among participants with greater working memory
capacity (Grenard et al., 2013). Another study conducted by the same group of authors also
showed that affective decision making ability interacted with spontaneous safe sex-related
associations to predict condom use – higher the affective decision making ability, greater the
condom use (Ames et al., 2013). Moreover, a study conducted by Mitchell et al., examining
the relationship between cognitive functioning and both drug- and sex-related HIV risk
behaviors among a sample of 229 injection drug users (IDUs) of heroin found that lower
cognitive function predicted higher HIV risk behavior (both drug- and sex-related) (Mitchell et
al., 2007). Studies proved that cognitive impairment is a high risk factor for HIV risk behaviors.
Impairment of cognitive functioning is not only exhibited among HIV infected individuals, but
also a very common phenomena among HIV negative drug users. Cognitive domains that are
commonly impaired in drug users are attention, memory, and learning (Indlekofer et al., 2009;
Lundqvist, 2005).

2.5 NCI and Self-efficacy
At a fundamental level, self-efficacy provides a perceived baseline by which people
plan their future behaviors. All forms of psychotherapy and behavioral change operate through
altering an individual's expectations of personal mastery and success – proposed by selfefficacy theory (Bandura, 1978). According to Bandura, two forms of expectancies - outcome
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expectancies (the belief that certain behaviors will lead to certain outcomes), and self-efficacy
expectancy (the belief that one can successfully perform the behavior in question) exhibit a
strong impact on behavior (Bandura, 1978). Self-efficacy expectancy is a more potent predictor
of behavior change, as it regulates the initial decision-making to perform a behavior, the effort
expended, and the persistence in any adverse situation (Bandura, 1978). Recognition of the
influence of self-efficacy on human behavior will lead to better understanding of the mechanism
of behavior change (Bandura, 1978). In addition, research on understanding the impact of selfefficacy may have implications for adjusting intervention procedures to achieve desirable
outcomes.
On the other hand, prior research has suggested an indirect effect of NCI on treatment
outcomes (Meade, Conn, Skalski, & Safren, 2011; Pabst, Kraus, Piontek, Mueller, & Demmel,
2014). It thus may be beneficial to study the impact of NCI on treatment outcomes within more
complex models that examine mediation and moderation relationships between NCI and one of
the most powerful predictors of behavior change, self-efficacy. To date, very few studies have
examined the interaction effect of NCI and self-efficacy on treatment outcomes. We have found
only one study conducted by Worley et al. (2014) that examined the effects of NCI on substance
abuse treatment outcomes (drinking or drug use) via self-efficacy among a sample of veterans.
Greater NCI indirectly predicted poorer treatment outcomes via lower self-efficacy (i.e.,
confidence to resist use of alcohol or drugs across a variety of high-risk situations) (Worley et
al., 2014). Thus, there has been very little investigation of the interaction of these particular
variables and their impact on various treatment outcomes.
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2.6 Self-efficacy and HIV Risk Behavior
Self-efficacy is a strong predictor of risk taking behaviors and treatment outcome
(Bandura, 1990; Burleson & Kaminer, 2005). The lower the perceived self-efficacy, the higher
the likelihood of engagement in high risk behaviors. Translating health information into
effective self-protection action against risk taking behaviors requires a sense of personal power
to exercise control over situations which depends on skills and self-efficacy (Bandura, 1990).
In HIV risk reduction intervention, information, motivation, and behavioral skills and selfefficacy are the key determinants of HIV risk reduction behavior (M. M. Copenhaver & Lee,
2006).
Studies showed that lower self-efficacy significantly predicted higher levels of HIV risk
behaviors (Bedoya et al., 2012; Nehl et al., 2015; Puffer et al., 2011; Thomas et al., 2009;
Winningham et al., 2004). A mediational study conducted by Miner et al., examined the
relationship between norms for condom use and unsafe sex (unprotected sex) via condom use
self-efficacy in a sample of HIV infected MSM (Miner et al., 2009). They stated norms for
condom use indirectly influenced unsafe sex through condom use self-efficacy in this sample.
They suggested researchers should consider the impact of condom use self-efficay on risk
behavior and intervenion should be designed to improve self-efficay (Miner et al., 2009). A
very recent study conducted by Pitpitan et al., aimed to test the mechanism of injection risk
intervention – how the intervention was reducing receptive needle sharing among female sex
workers who inject drugs (FSWs-IDUs) in Mexico by moderated mediational analysis (Pitpitan
et al., 2015). They showed that the intervention affected receptive needle sharing through safe
injection self-efficacy in this population – those who had more safe injection self-efficacy were
less likely to engage in needle sharing (Pitpitan et al., 2015). Studies documented that self-
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efficacy influenced HIV risk behavior (unprotected sex and needle sharing) both directly and
indirectly.

2.7 Gender Difference in NCI, Self-efficacy, and HIV Risk Behavior
Gender is another construct that plays a significant role in both self-efficacy and HIV risk
behavior (Buchanan et al., 2006; Copenhaver, Lee, & Baldwin, 2013; Corsi et al., 2014; Lee, Salman,
& Cooksey-James, 2016; Puffer et al., 2011; Stevens, Murphy, & McKnight, 2003; Zandmomen et al.,
2014). Additionally, some studies report greater NCI in women than men (Gandhi et al., 2010; Royal
et al., 2016; Shrestha et al., 2015; Troncoso & Conterno, 2015).

A study conducted by Corsi et al., intended to address the gender difference in predictors
of HIV status among PWID in Ukraine, reported higher self-efficacy in women than men, but
documented HIV risk behavior, both risky injection and risky sexual behavior, were more
common in women than men (Corsi et al., 2014). Another cross-sectional study by Zandmomen
et al., conducted on 400 HIV infected patients in Iran, also stated that women demonstrated
higher self-efficacy, but reported risky behavior was more in women as well (Zandmomen et
al., 2014). On the other hand, a study by Puffer et al., reported more sexual risky behavior and
less safe sex self-efficacy in men (Puffer et al., 2011).
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CHAPTER 3 : Hypotheses and Objectives

1st Objective: To analyze the influence of NCI on HIV preventive behaviors via self-efficacy.
1st Hypothesis: The influence of NCI on HIV preventive behaviors will be mediated by selfefficacy.
2nd Objective: To analyze the moderation effect of gender on relationship of NCI and HIV
preventive behaviors via self-efficacy.
2nd Hypothesis: The predicted mediation effect will be significantly moderated by gender.
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CHAPTER 4 : Methods

4.1 Design
This is a secondary data analysis that included a sample of HIV-negative opioid
dependent individuals who participated in a Community-Friendly Health Recovery Program
(CHRP; see http://www.nrepp.samhsa.gov/ProgramProfile.aspx?id=11), a behavioral HIV-risk
reduction intervention which was a randomized control trial designed to reduce HIV
transmission risk behavior among this risk population (M. M. Copenhaver et al., 2013). CHRP
is an abbreviated, manual-guided intervention strategy, based on the information–motivation–
behavioral skills (IMB) model of health behavior change, and comprised of four 1-hour group
sessions that address sex-and drug-related HIV risk behaviors among individuals with opioid
use disorders (OUDs), enrolled in Methadone Maintenance Therapy (MMT). The active control
condition also received same number of sessions as intervention condition, but the session
content was comprised of information regarding methadone program services and policies as
well as general health care information (e.g., community resources) relevant to opioiddependent patients entering methadone therapy. The sessions were conducted by bachelor’s
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level facilitators. The results of the RCT have been previously published (M. M. Copenhaver
et al., 2013).

4.2 Participants
The current study included 236 HIV-negative opioid-dependent individuals who
participated in the CHRP study and completed a 3-month follow-up assessment at the APT
Foundation, Inc., in New Haven, CT. The inclusion criteria for the participants were: (a) 18
years or older, (b) met DSM-V criteria for opioid dependence, (c) newly enrolled in MMT, (d)
reported sex- and/or drug-related HIV transmission risk behaviors in the past 6 months, and (e)
not actively suicidal, homicidal, or psychotic.

4.3 Procedures
The study protocol was approved by the Institutional Review Board (IRB) at the
University of Connecticut, the Human Investigation Committee at Yale University, and
received board approval from the APT Foundation MMP, Inc.
All patients enrolled in MMT were screened for eligibility within one week of receiving
the first methadone dose. Patients who were willing to participate in the study and also met the
inclusion criteria, were provided a verbal and written description of the study and were asked
to sign an informed consent form prior to random assignment to either the control (n = 115) or
intervention (n = 121) condition. Participants were reimbursed for the time required to complete
the assessments. An audio computer-assisted self-interview (ACASI) that has demonstrated
sound psychometric properties (M. M. Copenhaver & Lee, 2006; M. M. Copenhaver, Lee, &
Margolin, 2007; Fisher et al., 2004) was used to asses participants. In this current study, baseline
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NCI, post-intervention self-efficacy, and 3-month follow-up data regarding HIV prevention
intervention outcomes were included in our path analyses in order to examine the associations
among theoretical variables of interest.

4.4 Measures
Participants’ demographic details (gender, age, ethnicity, education, language, marital
status, and income) and NCI were recorded at baseline. Self-efficacy and HIV prevention
behavioral outcomes were measured at baseline, post-intervention, and follow-up.

4.4.1 NCI Measures
Participant’s neurocognitive status was evaluated by Brief Inventory of Neurocognitive
Impairment (BINI) (M. Copenhaver, Shrestha, Wickersham, Weikum, & Altice, 2016). BINI
is a brief, self-report measure of 57-items and 9-factors which demonstrated excellent overall
reliability (α=0.97). It was developed as a rapid and convenient way to help elicit diagnostically
relevant information about both generalized NCI which is labeled as “Global Impairment” and
specific symptom areas (e.g., attention, memory, linguistic functioning, etc.). Factors include
Global Impairment that measured by 22 items (e.g., “I have difficulty paying attention” and “I
get lost easily”), Academic-related contained 8 items (e.g., “I count with my fingers” and “I
have trouble learning new things”), Language-related had 5 items (e.g., “My words get mixed
up”), Memory-related was made up of 4 items (e.g., “I have trouble remembering people’s
names”), Psychomotor/physical comprised of 5 items (e.g., “I am very clumsy”),
Psychomotor/perceptual included 5 items (e.g., “I have trouble with the left side of my body”),
Anger-related had 3 items (e.g., “I have urges to break and smash things”), Pain-associated
contained 3 items (e.g., “I have severe headaches”), and Traumatic Head Injury-related had 2
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items (e.g., “I have been knocked unconscious”). The reliability of the 9 factors ranged from
excellent to good (by factor: F1 α=0.97; F2 α=0.89; F3 α=0.82; F4 α=0.76; F5 α=0.79; F6
α=0.75; F7 α=0.75; F8 α=0.74; F9 α=0.73).

4.4.2 Self-efficacy Measures
Self-efficacy related to HIV risk reduction was measured for drug- and sex-related risk
reduction behaviors separately as safe injection self-efficacy (SISE) and safe sex self-efficacy
(SSSE). To measure SISE, following items were used: (1) “How hard to abstain from
injecting?”, and (2) “How hard to always clean needle with bleach if you shared?”, whereas
SSSE was measured using two subsequent items: (1) “How hard to abstain from sex?”, and (2)
“How hard to always use condoms?”. All of these four items were measured by using 5-point
Likert scale (“0=Very hard to do”, “1=Fairly hard to do”, “2=Neither hard nor easy to do”,
“3=Somewhat easy to do”, “4=Very easy to do”). The sum of two items assessing SISE was
used to measure participant’s self-efficacy in drug-related risk reduction behavior and the sum
of other two items assessing SSSE was used to measure self-efficacy in sex-related risk
reduction behavior. Higher score indicated greater self-efficacy.

4.4.3 HIV Prevention Behavior Measures
Participants’ HIV preventive behaviors were assessed separately for drug- and sexrelated measures. Drug-related outcome included the use of clean needle use (CNU) as
measured by five items: (1) “Did you inject illicit drugs in the past 7 days?”, (2) “If you injected
drugs last week, have you shared rinse water?”, (3) “If you injected drugs last week, have you
shared a cooker?”, (4) “If you injected drugs last week, have you shared cotton?”, and (5) “Have
you used unclean needle or syringe after someone else?”. Sex-related outcome included
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condom use (CU) as measured by three items: (1) “Do you use condoms every time you have
sex?” (2) “Have you had oral, anal, or vaginal sex without using a condom, or other latex
protection in the past 6 months?”, and (3) “Do you inconsistently (sometimes or never) use
condoms or other latex protection for vaginal sex?”. “Yes” and “No” responses were used for
assessing all these items. The corresponding items were added to obtain the total score for each
measures. Higher score specified to higher CNU and CU. A recent confirmatory factor analysis
was conducted to define these items measuring CNU and CU (Huedo-Medina, Shrestha, &
Copenhaver, 2016).

4.5 Data Analysis
Analyses were designed to test our two hypotheses: (1) the effects of NCI (Independent
Variable: IV) on HIV risk reduction behavior (Dependent Variable: DV) will be mediated by
self-efficacy related to HIV risk reduction behavior (Mediator: Me), and (2) this mediation
effect will be moderated by gender (Moderator: Mo).
Data analysis was conducted as follows: (1) Normality test was conducted for DV. Both
subjective tests (Histograms and Q-Q plots) and objective tests (Shapiro-Wilk, KolmogorovSmirnov, Cramer-von Mises and Anderson-Darling) were used to specify the for participants’
distribution of data. (2) All assumptions of regression (linearity, homoscedasticity, and
normality of residuals) were checked. (3) Descriptive statistics were provided for demographics
and variables of interest. (4) In order to test our first hypothesis, we conducted mediation
analysis by following the approach proposed by Imai et al. (Imai, Keele, Tnigley, & Yamamoto,
2010). First, HIV risk reduction self-efficacy (Me) was regressed on NCI (IV). Subsequently,
HIV risk reduction behavior (DV) was regressed on NCI (IV) and self-efficacy (Me) controlling
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for covariates. Finally, we estimated the average causal mediation effect (ACME), average
direct effect (ADE), total effect (TE), and proportion of direct effect mediated by using the
‘mediation’ package in R (Imai et al., 2010). We reported results from Quasi Bayesian analysis.
(5) In order to test our second hypothesis, whether the mediation effect depends on the level of
gender, we incorporated gender as a moderator in path a, b, and c´, and tested the moderated
mediation model. A significant interaction effect of gender with IV/Me is indicative of a
moderated mediation effect. Our preliminary mediation models controlled for participants’
demographics (gender, age, ethnicity, education, language, marital status, and income), group,
and baseline HV risk reduction behaviors (CNU/CU). Aside from Gender, Group and
demographics were not significantly associated with 3-month follow-up CNU and CU. Thus,
in our final mediation models, we only controlled for baseline HIV risk reduction behavior
(CNU/CU) and Gender. Further, in the moderated mediation models, we integrated Gender as
a moderator and controlled for baseline CNU/CU. There were no missing values in the summed
scores of CNU and CU.
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CHAPTER 5 : Results

5.1 Normality test
Normality test was carried out for both dependent variables (CNU and CU). We used
subjective tests (Histograms and Q-Q plots) and as well as objective tests (Shapiro-Wilk,
Kolmogorov-Smirnov, Cramer-von Mises and Anderson-Darling) to specify the distribution of
our dependent variables. Histogram, Q-Q plot, and Tests for Normality for CNU showed that
distribution was approximately normal. Along with Tests for Normality (Figure 5), bell-shaped
Histogram provided support for normal distribution (Figure 6) and as well as Q-Q plot (Figure
7).
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Figure 5: Tests for Normality of 3-Month Follow-up Clean Needle Use

Figure 6: Histogram for 3-Month Follow-up Clean Needle Use
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Figure 7: Q-Q Plot for 3-Month follow-up Clean Needle Use
Similarly, for CU, Tests for normality (Figure 8), bell-shaped Histogram (Figure 9), and
Q-Q plot (Figure 10) demonstrated approximately normal distribution.
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Figure 8: Tests for Normality of 3-Month Follow-up Condom Use

Figure 9: Histogram for 3-Month Follow-up Condom Use
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Figure 10: Q-Q Plot for 3-Month Follow-up Condom Use

5.2 Checking Assumptions of Regression
5.2.1 Linearity
Scatterplot did not indicate straight line linear relationship between IV (NCI) and DV
(CNU/CU) (Figure 11, 13), and Me (SISE) and DV (CNU/CU) (Figure 12, 14).
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Figure 11: Scatterplot of 3-Month Follow-up Clean Needle use Vs Baseline
Neurocognitive Impairment

Figure 12: Scatterplot of 3-Month Follow-up Clean Needle use Vs Post-Intervention Sefe
Injection Self-efficacy
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Figure 13: Scatterplot of 3-Month Follow-up Condom use Vs Baseline Neurocognitive
Impairment

Figure 14: Scatterplot of 3-Month Follow-up Condom use Vs Post-Intervention Safe Sex
Self-efficacy
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5.2.2 Homoscedasticity of Residuals
Residuals for CNU (Figure 15, 16) and CU (Figure 17, 18) were randomly scattered
around zero and studentized residuals did not create any pattern, which indicated constant
variance.

Figure 15: Plot of Residuals of 3-Month Follow-up Clean Needle Use (against Baseline
Neurocognitive Impairment)

Figure 16: Plot of Residuals of 3-Month Follow-up Clean Needle Use (against PostIntervention Safe Injection Self-efficacy)
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Figure 17: Plot of Residuals of 3-Month Follow-up Condom Use (against Baseline
Neurocognitive Impairment)

Figure 18: Plot of Residuals of 3-Month Follow-up Condom Use (against PostIntervention Safe Sex Self-efficacy)

5.2.3 Normality of Residuals
Residuals for CNU (Figure 19, 20) and CU (Figure 21, 22) were normally distributed.
Histograms for residuals of CNU (Figure 19) and CU (Figure 21) were Bell-shaped and in QQ plot there were not any definite curve (Figure 20, 22), though data were above and below the
line which indicated skewness.
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Figure 19: Histogram of Residuals of 3-Month Follow-up Clean Needle Use against (A)
Baseline Neurocognitive Impairment (IV) & (B) Post-Intervention Safe Injection Selfefficacy (Me)

Figure 20: Q-Q Plot of Residuals of 3-Month Follow-up Clean Needle Use against (A)
Baseline Neurocognitive Impairment (IV) & (B) Post-Intervention Safe Injection Selfefficacy (Me)
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Figure 21: Histogram of Residuals of 3-Month Follow-up Condom Use against (A)
Baseline Neurocognitive Impairment (IV) & (B) Post-Intervention Safe Sex Self-efficacy
(Me)

Figure 22: Q-Q Plot of Residuals of 3-Month Follow-up Condom Use against (A)
Baseline Neurocognitive Impairment (IV) & (B) Post-Intervention Safe Sex Self-efficacy
(Me)
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5.3 Descriptive Statistics
Among all participants (n = 236, 108 males), a majority were Caucasian (73.73%), never
married (66.1%), English-speaking (94.92 %), with 12 years of education (47.46%), annual
income less than $11,000 (86.09%), and median age of 34 (Table 1). All participants had some
degree of neurocognitive impairment (Figure 23). The mean scores of SISE, SSSE, CNU, and
CU were 6.74 (±1.62), 4.19 (±2.54), 3.82(±0.70), and 0.72(±0.89), respectively (Table 2).

Table 1: Demographic characteristics of participants (n = 236)
Participants
Frequency
Percentage
Gender
Ethnicity

Years of
Education

Marital
status

Income

Language
Age

Male
Female
White
African American
Hispanic / Latino
Other
6 or below
12 or below
16 or below
More than 16
Married
Never married
Separated
Divorced
Widowed
0 to $10,999
$11,000 to $20,999
$21,000 to $30,000
Over $30,000
English
Spanish
Median
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108
128
174
23
33
6
4
112
8
2
22
156
19
35
4
99
8
4
4
224
12

46
54
73.73
9.75
13.98
2.54
1.69
47.46
3.39
0.85
9.32
66.10
8.05
14.83
1.69
86.09
6.96
3.48
3.48
94.92
5.08
34

Table 2: Summary statistics of HIV risk reduction self-efficacy and behaviors
Participants Variables
Mean
Std Dev
Min
Max
SISE
6.74
1.62
1
8
SSSE
4.19
2.54
0
8
236
CNU
3.83
0.70
0
5
CU
0.72
0.89
0
3

Figure 23: Prevalence of neurocognitive impairment
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5.4 Mediation Test
In order to conduct mediation analysis following the rules of Baron and Kenny (Baron
& Kenny, 1986), we first tested the effects of baseline NCI on 3-month follow-up HIV risk
reduction behavior and post-intervention self-efficacy to examine whether the predictor
(baseline NCI) was significantly associated with the outcome (3-month follow-up CNU/CU)
and mediator (post-intervention SISE/SSSE). Higher NCI significantly predicted lower CNU
(β = -0.006, p = 0.03), but not CU (β = -0.0008, p = 0.81). Higher NCI also significantly
predicted lower SISE (β = -0.016, p = 0.016) and lower SSSE (β = -0.023, p = 0.024). After
establishing the relationship between predictor and mediator, we examined whether the
mediator predicted future outcome. SISE and SSSE were tested separately as predictor of CNU
and CU, controlling for predictor (NCI) and covariates (Baseline CNU/CU and gender). Greater
SISE and SSSE significantly predicted higher future CNU (β = 0.098, p ˂ 0.001) and CU (β =
0.137, p ˂ 0.001), respectively. With these results providing reasonable support for mediation,
we conducted causal mediation analyses (using ‘mediation’ package) and estimated ACME,
ADE, and TE for both CNU model and CU model (Imai et al., 2010).
For the CNU model, where we controlled for baseline CNU and gender, (Figure 24),
ACME was significant, the effect of NCI on CNU was significantly mediated by SISE (β= 0.0016, CI [-0.003, -0.0003], p= 0.02, proportion of direct effect mediated 25%). The direction
of relationship between NCI and SISE (β=-0.016, p=0.01), and the relationship between SISE
and CNU (β=0.098, p<0.001) indicated that greater NCI predicted lower SISE, and lower SISE,
in turn, predicted lower future CNU (at follow-up). The ADE of NCI on CNU (controlling for
SISE) was not significant (β= -0.004, CI [-0.009, 0.001], p= 0.13), but the TE of NCI on CNU
was significant (β= -0.006, CI [-0.01, -0.0004], p= 0.03). The estimate of total effect (β= -0.006)
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was larger than the estimate of direct effect (β=-0.004) and also the direct effect was not
significant, but the total effect was significant – which establishes complete mediation (Baron
& Kenny, 1986).

Figure 24: Causal mediation analysis – Clean Needle Use (CNU) Model
Similarly, ACME was significant for CU model, controlling for baseline CU and gender
(Figure 25), the effect of NCI on CU was also significantly mediated by SSSE (β= -0.003, CI
[-0.006, -0.0004] p= 0.02, proportion of direct effect mediated 59%). The estimates of NCI and
SSSE (β=-0.023, p=0.02), and SSSE and CU (β=0.137, p<0.001) showed that greater NCI also
predicted lower SSSE, and lower SSSE, in turn, predicted lower future CU. Both TE of NCI on
CU (β= -0.0008, CI [-0.007, 0.006], p= 0.81) and ADE of NCI on CU (controlling for SSSE)
(β= 0.002, CI [-0.003, 0.009], p= 0.47) were not significant and the direction of direct effect
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(β= 0.002) was opposite to the direction of indirect effect (β= -0.003) – which suggests
inconsistent mediation (David P. MacKinnon, Fairchild, & Fritz, 2007).

Figure 25: Causal mediation analysis - Condom Use (CU) Model

5.5 Moderated Mediation Test
In order to test our second hypothesis, that the indirect effects of NCI on HIV risk
reduction behavior via self-efficacy would be significantly moderated by gender, we examined
the moderation effect of gender on the relationship between NCI and self-efficacy, and also on
the relationship between self-efficacy and HV risk reduction behavior.
For the CNU model, gender moderated both path b and c´, the relationship between
SISE and CNU, and the relationship between NCI and CNU, respectively. The interaction
effects between gender and SISE (β= 0.092, p= 0.06), and gender and NCI (β= 0.01, p= 0.06)
were slightly significant. Given that this result provided support for moderated mediation, we
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estimated ACME for males and females separately, and the mediation effect was significant for
females (β= -0.002, CI [-0.005, 0.00001], p= 0.06, proportion of direct effect mediated 47%).
Though the p-value was only marginally significant and the CI contains zero, the proportion of
direct effect of NCI on CNU mediated by SISE was significant (47%).
For the CU model, we did not find any significant interaction effect regarding gender.
As, gender was a significant moderator in our CNU model and previous studies, we estimated
ACME for males and females separately; however, we did find a significant mediation effect
for females (β= -0.006, CI [-0.012, -0.002], p= 0.00, proportion of direct effect mediated 80%).
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CHAPTER 6 : Discussion

In our sample, self-efficacy mediated the relationship of NCI on HIV risk reduction
behaviors for both clean needle use and condom use, and these mediation effects were
significant only for females. This is the first study to date to explore the complex relationship
of NCI, self-efficacy, gender, and HIV risk reduction behavior among OUDs within a treatment
setting. Our study developed a theoretical framework that establish a mediation effect of selfefficacy in the relationship between NCI and key HIV risk reduction behaviors (e.g., clean
needle use and condom use) that varied significantly as a function of gender.
The results of the CNU model demonstrated that participants’ greater drug-related HIV
risk reduction behavior (i.e., clean needle use) was predicted by lower NCI, and this relationship
was completely mediated by their HIV risk reduction self-efficacy (i.e., safe injection selfefficacy), as the direct effect was not significant, but the total effect was significant. The effect
of NCI on CNU was going directly through SISE – with lower NCI predicting higher SISE, and
higher SISE predicting greater CNU.
When we examined the CU model, the effect of NCI on HIV risk reduction behavior
(i.e., condom use) was inconsistently mediated by HIV risk reduction self-efficacy (i.e., safe
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sex self-efficacy), as both the direct effect and the total effect were not significant. In this case,
lower NCI did not predict greater CU, but rather predicted higher SSSE, and higher SSSE
predicted greater CU. We note, however, inconsistent mediation does not indicate an absence
of significant findings; rather, it indicates mediation which occurs in the absence of a significant
total effect and direct effect when the mediator functions as a suppressor variable or in the
context of undetected moderator effects (David Peter MacKinnon, 2008). We also note that
prior research has shown a similar pattern of inconsistent mediation effects of self-efficacy on
substance use outcomes as well (Worley et al., 2014).
In this study, the mediation effects of self-efficacy for both clean needle use and condom
use models were moderated by gender (only for females). Thus, gender moderated the
relationship between self-efficacy and HIV risk reduction behavior.
Overall, the results are consistent with previous research – lower neurocognitive
impairment was shown to be associated with higher self-efficacy (Bates, Pawlak, Tonigan, &
Buckman, 2006; Worley et al., 2014) and lower HIV risk reduction behaviors (Ezeabogu et al.,
2012; Gonzalez et al., 2005; Schuster, Crane, Mermelstein, & Gonzalez, 2012; Shrestha &
Copenhaver, 2016). Prior studies also predicted greater self-efficacy to be associated with
higher HIV risk reduction behavior (Bedoya et al., 2012; Nehl et al., 2015; Puffer et al., 2011;
Thomas et al., 2009). Interestingly, we found a significant mediation effect of self-efficacy in
the relationship between neurocognitive impairment and HIV risk reduction behaviors, only in
females. This results show that self-efficacy is a significant predictor of HIV risk reduction
behaviors for female drug users, which is supported by previous research where females were
more likely than males to respond with improvement in self-efficacy (Corsi et al., 2014).

~ 43 ~

Taken together, the results indicate the need for future studies to develop and test
intervention strategies that better accommodate the effects of NCI on key intervention outcomes
including self-efficacy, particularly for female participants. Many interventions target both
genders at the same time without considering specific behavioral components (e.g., selfefficacy) and cognitive status (e.g., NCI). However, previous research has shown that
interventions are more effective when targeting high risk populations, a specific gender (either
men or women), and behavioral components/skills training (Crepaz et al., 2006; Huedo-Medina
et al., 2010; Scott-Sheldon, Huedo-Medina, Warren, Johnson, & Carey, 2011; Tan, HuedoMedina, Warren, Carey, & Johnson, 2012). The positive association between self-efficacy and
HIV risk reduction behavior in our study underlines the need to address self-efficacy to improve
HIV risk reduction, particularly in the programs those geared toward female drug users.
Information or skills that can enhance self-efficacy of condom use and clean needle use may be
essential to be included in order to have an effective HIV prevention intervention program.
Better accommodation of the effects of NCI by repeating the information and skills, and a
gender-specific intervention that aims to improve self-efficacy could positively influence HIV
risk reduction behavior, such as clean needle use and condom use.
This current study has several limitations. Firstly, the study was conducted in a drug
treatment setting among drug users which restricts our ability to generalize the findings to other
risk populations, such as non-drug involved populations, non-treatment settings, or to persons
not meeting our inclusion criteria including a readiness to participate. In addition, the majority
of the sample was Caucasian, and that also limits the generalizability of our results to more
ethnically diverse populations. Secondly, as the participants were newly enrolled individuals in
a methadone maintenance drug treatment facility, the risk reduction effects that methadone
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exerts on drug use and related HIV risk behaviors (Amato et al., 2013; Maremmani, Pani,
Pacini, & Perugi, 2007; Otiashvili et al., 2013; Shi et al., 2007) may have influenced the effects
of mediators and moderators on the HIV risk reduction outcomes. Thirdly, we did not include
behavior skills in our analysis, although, theoretically, skills are sometimes included in the
measurement of self-efficacy. Finally, all assessments were based on self-report in the primary
RCT study which carries with it inherent limitations due to participants’ possible reluctance to
self-report socially unacceptable behaviors (Turner, Rogers, Hendershot, Miller, & Thornberry,
1996). This might have been reduced, however, by the use of ACASI (Audio Computer
Assisted Self-Interview) system, which allowed participants to respond with a high level of
privacy.
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CHAPTER 7 : Summary & Future Directions

Understanding how cognitive impairment impact drug- and sex-related HIV risk
reduction behaviors is essential to reduce HIV risk effectively (Anand et al., 2010). The current
study provides preliminary evidence that neurocognitive impairment adversely impacts drugand sex-related HIV risk reduction outcomes through the mediating variable of self-efficacy.
Previous research showed that cognitive deficits influence HIV risk behaviors among drug
users, as the cognitive domains that are affected in drug users are essential to acquire, retain,
and utilize HIV preventive behaviors (M. Copenhaver, Avants, Warburton, & Margolin, 2011).
It is important to develop a treatment strategy where we can accommodate cognitive
impairment to prevent HIV risk behaviors for this population. Multimodal presentation of
material (e.g., verbally, visually, and experimentally) is a very effective way for the cognitively
impaired participants to retain information and skills. In the parent study, during the group
sessions, information was provided both verbally and visually. Participants were encouraged to
engage in treatment process by asking questions. Additionally, during teaching the risk
reduction behaviors skills, the proper procedure of cleaning the injection equipment and the
proper application of condom by using a penis replica were demonstrated by showing video
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clips. Participants also practiced these risk reduction skills during the sessions which helped
them to retain the information and skills. Visual, verbal, and experimental presentation of
materials increases concentration and aids to avoid fatigue in cognitively impaired populations
who get tired easily. Moreover, frequent review of materials helped with the retention of
information, building confidence, and skills. To develop an appropriate treatment strategy, it is
essential to identify when cognitive impairment may impact full participation. We did not set a
diagnostic cut point when we measured NCI in this study, but doing so in future work could be
beneficial to help clinicians identify when NCI is a significant barrier for HIV treatment/
prevention. Thus, it was not the focus of the present study, but should be addressed in future
studies aimed at better screening and accommodating NCI.
Moreover, previous studies have demonstrated that evidence based interventions (EBI)
incorporating cognitive remediation strategies - with an emphasis on practical applications (e.g.
motivation, self-efficacy, skills and role-play) - are the most effective at reducing risk among
cognitively impaired populations (Kalichman, 2008). In this current study, we found that selfefficacy predicted HIV risk reduction behavior significantly and, furthermore, self-efficacy was
predicted by NCI. Overall, self-efficacy significantly mediated the relationship between NCI
and HIV risk reduction behavior. In addition, the mediation effect of self-efficacy was
moderated by gender and the mediation was significant only for women in this sample of
PWUDs, which indicates the need of future studies aiming to improve self-efficacy, particularly
for female drug users with neurocognitive impairment to reduce HIV risk behaviors. Recent
work indicates that the pattern of cognitive difficulties, like, impairment in memory,
information processing, and decision making in drug users may be addressed in future
interventions by incorporating mHealth (mobile health) or Pre-Exposure Prophylaxis (PrEP).
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Recognizing and understanding these components, and tailoring interventions accordingly
seems to be essential in order to optimize intervention approaches that targeting this population.
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